ClinicalTrials.gg
RecruitingNCT06731881LIGHTUpdated Jun 11, 2026

Assessing the Efficacy of Photodynamic Therapy for Preventing Surgical Site Infections

An interventional study of Nasal PDT and Photosensitizer formulation only in Surgery, Nasal Disease and Light; Therapy, Complications, sponsored by Guy's and St Thomas' NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Guy's and St Thomas' NHS Foundation Trust · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

This is a randomised, unblinded interventional device proof of concept pilot trial in which patients undergoing nasal surgery will be selected for either photodisinfection therapy (PDT) with the Steriwave™ ND System, or control with nares swabbed with 'photosensitizer formulation' preoperatively.

This trial will primarily assess the safety and efficacy of nasal photodisinfection treatment in decreasing post-operative events in patients undergoing nasal surgery. After signing informed consent, and before surgery, participants will receive a baseline culture of the anterior nares to determine nasal bacterial colonization and will have a flexible nasendoscopy to determine their Lund-Kennedy (LK) endoscopic score. Subjects will then be randomised to nasal PDT (which includes two applications of 'photosensitizer formulation' [0.01% methylene blue with 0.25% chlorhexidine solution], two minutes apart), along with light therapy, or control with nares swabbed twice with 'photosensitizer formulation' with two minutes in between (no light therapy). Following treatment, participants will be re-cultured (2 weeks after the surgery ± 7 days) and reviewed for antibiotic use and surgical site infection (SSI) using LK endoscopic scoring. At 30 days, all participants will be followed up by telephone to review if they received antibiotics for presumed postoperative infection. Standard post-operative care will be provided according to the type of surgery performed. Any required interventions post-operatively will be documented.

Read the detailed description

Preoperative nasal decolonisation has been shown to achieve significant reductions in surgical site infections at sites remote from the nasal cavity. It would therefore seem to have great potential in reducing the risk of post-operative infections after sinonasal surgery, and therefore reduce antibiotic usage. If surgeons have confidence in the treatment, those that routinely prescribe prophylactic antibiotics may also be pursued to change their practice.

The aim of this study is to assess the efficacy and safety of photodisinfection therapy versus control with nares swabbed with 'photosensitizer formulation' (0.01% methylene blue with 0.25% chlorhexidine solution) to reduce the antibiotics usage for presumed SSI inpatients undergoing nasal surgery. The investigators hypothesise that preoperative photodisinfection will demonstrate greater efficacy compared to control with nares swabbed with 'photosensitizer formulation' (0.01% methylene blue with 0.25% chlorhexidine solution) in reducing the usage of antibiotics for presumed surgical site infection (SSI) among patients undergoing nasal surgery.

The investigators will also further evaluate the effectiveness of nasal decolonisation in eliminating colonization of the anterior nares with S. aureus and other potentially pathogenic microbes. The anterior nares are often considered the primary reservoir of S. aureus and other pathogens on the body (36). Therefore, this product could play an important role in helping to eliminate the anterior nares as a pathogen reservoir in surgical patients.

This study is meant to provide further safety, efficacy, and methodological data, but is not intended to establish definitive statistical significance. If required, this study will support a subsequent larger study that would establish statistical significance for the reduction of surgical site infections, but which is currently not the subject of this protocol.

02

Conditions studied

  • Surgery
  • Nasal Disease
  • Light; Therapy, Complications

Keywords

  • nasal surgery
  • nasal photodisinfection
  • decolonisation
  • surgical site infection
03

In context

Nose Diseases

22 studies on the registry are indexed under Nose Diseases; 9 are open to participants now.

This study's planned enrollment of 80 is below the median of 99 across 18 interventional studies indexed under Nose Diseases.

Browse Nose Diseases studies →

Lead sponsor

Guy's and St Thomas' NHS Foundation Trust is the lead sponsor of 295 studies on the registry; 80 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 16 years
  • Patients scheduled to undergo elective:

    • Endoscopic Sinus Surgery (ESS) with or without adjunctive Septoplasty and/or Turbinoplasty
    • Septoplasty with or without adjunctive Turbinoplasty
    • Closed Septoplasty with or without adjunctive Turbinoplasty
  • Judged by the Investigator as suitable for participation in the study without safety concerns based on medical history and physical examination
  • Willing and able to provide written prior to participation in the clinical investigation
  • Willing and able to comply with all study related procedures

Exclusion criteria

Exclusion Criteria:

-• Patients undergoing open septorhinoplasty, anterior or septal , or post cautery

  • Congenital or acquired immunodeficiency, bone marrow disease, diabetes, conditions requiring treatment, any immunosuppressive medication at the time of consent or within the last 4 weeks before randomisation
  • Primary or secondary ciliary dyskinesia, cystic fibrosis
  • Patients who have received antibiotics within a week before randomisation
  • Patients who receive prophylactic antibiotics or antibiotics prior to discharge
  • Systemic treatment less than 4 weeks before randomisation
  • History of frequent nose bleeds, or a condition that increases the risk of excessive bleeding
  • Undergoing active cancer treatment at time of consent/ or planning to start cancer treatment within trial period or completed cancer treatment within the last 4 weeks
  • Any disease, condition (medical or surgical), or drug or alcohol abuse, which, in the opinion of the investigator, might compromise the study results, or would place the patient at increased risk of infection
  • Previously treated with radiation on the face, head, or neck regions
  • Female patients who are pregnant or breastfeeding at the time of consent
  • Received a study drug in a clinical trial for an drug within the previous 30 days from consent, or 5 half-lives, whichever is longer
  • Used antimicrobial wash or wipes within 7 days of randomisation or during the study period
  • Patients with allergies / to methylene blue, polymethyl methacrylate (PMMA), or to chlorhexidine gluconate (CHG)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Photodisinfection

    The photodisinfection product consists of a CE-marked light source (SW4000), a disposable single-use nasal light diffuser, and a single-use photosensitiser applicator that can be used in hospital settings.

    Device: Nasal PDT · Other: Standard follow-up · Diagnostic Test: Nasal culture · Diagnostic Test: Flexible nasendoscopy · Other: In-person review · Other: Telephone Follow-up

  • Active comparator
    Control

    The control group will have nares swabbed with 'photosensitizer formulation' (0.01% methylene blue with 0.25% chlorhexidine solution) prior to surgery.

    Combination Product: Photosensitizer formulation only · Other: Standard follow-up · Diagnostic Test: Nasal culture · Diagnostic Test: Flexible nasendoscopy · Other: In-person review · Other: Telephone Follow-up

Interventions

  • DeviceNasal PDT

    Two two-minute cycles will be provided by a member of the research team in the pre-operative area on the day of surgery. A saturated swab containing 0.01% methylene blue and 0.25% chlorhexidine gluconate will be applied to nares, which is then activated by light.

    Also known as: Steriwave (SW4000)

  • Combination productPhotosensitizer formulation only

    Nares will be swabbed with Photosensitizer formulation (0.01% methylene blue with 0.25% chlorhexidine solution). Nasal swab cultures will be obtained before control swabbing and converted to colony-forming units to measure bacterial burden at baseline, and after treatment (2 weeks +/- 7 days). Sinonasal mucosal inflammation using the Flexible Nasendoscopy Endoscopic LK Score will also be obtained before treatment at 2 weeks (+/-7 days).

  • OtherStandard follow-up

    All patients will receive standard post-operative wound follow up. This might include being advised to contact the GP or the hospital if there are any wound problems and, or, being invited to an out-patient clinic appointment.

  • Diagnostic testNasal culture

    Nasal swab cultures will be obtained before Nasal PDT or control swabbing and converted to colony-forming units to measure bacterial burden at baseline, and after treatment (2 weeks +/- 7 days).

  • Diagnostic testFlexible nasendoscopy

    Sinonasal mucosal inflammation using the Flexible Nasendoscopy Endoscopic Lund-Kennedy (LK) Score will also be obtained before Nasal PDT or control swabbing and at 2 weeks (+/-7 days).

  • OtherIn-person review

    On Week 2 (±7 days), the participant will undergo an in-person review conducted in the ENT Outpatient department, 2nd floor Southwark wing, Guy's Hospital by the CI, PI or Co-investigator. During this appointment, concomitant medications and use of post-operative antibiotics will be reviewed.

  • OtherTelephone Follow-up

    On day 30, the research nurse will telephone participants from the ENT research office. * Review of adverse events/adverse device effects * Review of concomitant medications * Signs and symptoms post-surgery * Nasal washout * Record any use of post-operative antibiotics, both local and systemic

06

What researchers measure

Primary outcomes

  1. Antibiotic usage in number and percentages

    The proportion of patients requiring antibiotic therapy for presumed surgical site infections (SSIs) within 30 days after undergoing nasal surgery. Specifically, the intention is to compare those who received preoperative PDT with those in the control group.

    Time frame: 30 days

Secondary outcomes

  1. Incidence of surgical site infection

    The proportion of patients developing a postoperative infection within 30 days of surgery, defined by the presence of sinus purulence (Lund-Kennedy score of 2: 'Thick and purulent discharge') on nasal endoscopy and requiring antibiotic treatment.

    Time frame: 30 days

  2. Lund-Kennedy Score Assessment

    The change in Lund-Kenned (LK) scores from baseline during the study period, as measured by flexible nasendoscopy, in patients who received preoperative PDT compared to those in the control group. Each side is graded on an ordinal scale from 0-2, with higher scores indicating worse disease.

    Time frame: 30 days

  3. Bacterial Nasal Culture Rates

    The percentage of patients with positive bacterial cultures (S. aureus and Group A Streptococcus) from nasal swabs during the study period, comparing the PDT group with the control group.

    Time frame: 30 days

Other outcomes

  1. Safety of PDT

    The incidence of adverse events or complications (e.g., nasal irritation, bleeding, discomfort) associated with the nasal photodisinfection procedure, as reported by patients and assessed by clinical examination during the study period.

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Psaltis AJ, Li G, Vaezeafshar R, Cho KS, Hwang PH. Modification of the Lund-Kennedy endoscopic scoring system improves its reliability and correlation with patient-reported outcome measures. Laryngoscope. 2014 Oct;124(10):2216-23. doi: 10.1002/lary.24654. Epub 2014 Apr 2. PubMed 24615873 ↗
  • Carrie S, O'Hara J, Fouweather T, Homer T, Rousseau N, Rooshenas L, Bray A, Stocken DD, Ternent L, Rennie K, Clark E, Waugh N, Steel AJ, Dooley J, Drinnan M, Hamilton D, Lloyd K, Oluboyede Y, Wilson C, Gardiner Q, Kara N, Khwaja S, Leong SC, Maini S, Morrison J, Nix P, Wilson JA, Teare MD. Clinical effectiveness of septoplasty versus medical management for nasal airways obstruction: multicentre, open label, randomised controlled trial. BMJ. 2023 Oct 18;383:e075445. doi: 10.1136/bmj-2023-075445. PubMed 37852641 ↗
  • Rochon M, Jawarchan A, Ingusan S, Cariaga K and Morais C. 'Project ID007672: Clinical audit of patient-reported antibiotics for wound problems following surgery and review of alternative strategies'. 2023 Feb 25. Unpublished.
  • Street CN, Pedigo L, Gibbs A, Loebel NG. Antimicrobial photodynamic therapy for the decolonization of methicillin-resistant Staphylococcus aureus from the anterior nares, Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 73803B (13 July 2009); https://doi.org/10.1117/12.828279
  • Ontario Health (Quality). Pre-surgical Nasal Decolonization of Staphylococcus aureus: A Health Technology Assessment. Ont Health Technol Assess Ser. 2022 Aug 23;22(4):1-165. eCollection 2022. PubMed 36160757 ↗
  • Hsiao CJ, Paulson JN, Singh S, Mongodin EF, Carroll KC, Fraser CM, Rock P, Faraday N. Nasal Microbiota and Infectious Complications After Elective Surgical Procedures. JAMA Netw Open. 2021 Apr 1;4(4):e218386. doi: 10.1001/jamanetworkopen.2021.8386. PubMed 33914049 ↗
  • Bryce E, Wong T, Forrester L, Masri B, Jeske D, Barr K, Errico S, Roscoe D. Nasal photodisinfection and chlorhexidine wipes decrease surgical site infections: a historical control study and propensity analysis. J Hosp Infect. 2014 Oct;88(2):89-95. doi: 10.1016/j.jhin.2014.06.017. Epub 2014 Aug 1. PubMed 25171975 ↗
  • Braham P, Herron C, Street C, Darveau R. Antimicrobial photodynamic therapy may promote periodontal healing through multiple mechanisms. J Periodontol. 2009 Nov;80(11):1790-8. doi: 10.1902/jop.2009.090214. PubMed 19905948 ↗
  • Andersen R, Loebel N, Hammond D, Wilson M. Treatment of periodontal disease by photodisinfection compared to scaling and root planing. J Clin Dent. 2007;18(2):34-8. PubMed 17508621 ↗
  • Andersen R, Loebel N. Photodynamic Disinfection in the Treatment of Chronic Adult Periodontitis: A Multicentre Clinical Trial. J Dent Health Oral Disord Ther 2017, 8(4): 00289. DOI: 10.15406/jdhodt.2017.08.00289
  • Dinis-Ribeiro M, Moreira-Dias L. There is no clinical evidence of consequences after methylene blue chromoendoscopy. Gastrointest Endosc. 2008 Jun;67(7):1209. doi: 10.1016/j.gie.2007.12.043. No abstract available. PubMed 18513562 ↗
  • ASGE Technology Committee; Thosani N, Abu Dayyeh BK, Sharma P, Aslanian HR, Enestvedt BK, Komanduri S, Manfredi M, Navaneethan U, Maple JT, Pannala R, Parsi MA, Smith ZL, Sullivan SA, Banerjee S. ASGE Technology Committee systematic review and meta-analysis assessing the ASGE Preservation and Incorporation of Valuable Endoscopic Innovations thresholds for adopting real-time imaging-assisted endoscopic targeted biopsy during endoscopic surveillance of Barrett's esophagus. Gastrointest Endosc. 2016 Apr;83(4):684-98.e7. doi: 10.1016/j.gie.2016.01.007. Epub 2016 Feb 11. PubMed 26874597 ↗
  • Millson CE, Thurrell W, Buonaccorsi G, et al. The effect of low power laser light at different doses on gastric mucosa sensitised with methylene blue, hematoporphyrin derivative or toluidine blue. Laser Med Sci 1997; 12:145-150.
  • Sturmey RG, Wild CP, Hardie LJ. Removal of red light minimizes methylene blue-stimulated DNA damage in oesophageal cells: implications for chromoendoscopy. Mutagenesis. 2009 May;24(3):253-8. doi: 10.1093/mutage/gep004. Epub 2009 Feb 13. PubMed 19218330 ↗
  • Olliver JR, Wild CP, Sahay P, Dexter S, Hardie LJ. Chromoendoscopy with methylene blue and associated DNA damage in Barrett's oesophagus. Lancet. 2003 Aug 2;362(9381):373-4. doi: 10.1016/s0140-6736(03)14026-3. PubMed 12907012 ↗
  • Davies J, Burke D, Olliver JR, Hardie LJ, Wild CP, Routledge MN. Methylene blue but not indigo carmine causes DNA damage to colonocytes in vitro and in vivo at concentrations used in clinical chromoendoscopy. Gut. 2007 Jan;56(1):155-6. doi: 10.1136/gut.2006.107300. No abstract available. PubMed 17172595 ↗
  • Canto MI, Setrakian S, Petras RE, Blades E, Chak A, Sivak MV Jr. Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc. 1996 Jul;44(1):1-7. doi: 10.1016/s0016-5107(96)70221-3. PubMed 8836709 ↗
  • Kohli Y, Pfeiffer CJ, Kutty KP, Barrowman JA, Heughan C, Kepkay DL. Endoscopic diagnosis of intestinal metaplasia in Canada and Japan. J Clin Gastroenterol. 1981;3 Suppl 1:29-33. doi: 10.1097/00004836-198100031-00006. PubMed 7328294 ↗
  • Suzuki S, Suzuki H, Endo M, Takemoto T, Kondo T. Endoscopic diagnosis of early cancer and intestinal metaplasia of the stomach by dyeing. Int Surg. 1973 Sep;58(9):639-42. No abstract available. PubMed 4744424 ↗
  • Shah-Khan MG, Lovely J, Degnim AC. Safety of methylene blue dye for lymphatic mapping in patients taking selective serotonin reuptake inhibitors. Am J Surg. 2012 Nov;204(5):798-9. doi: 10.1016/j.amjsurg.2012.02.004. Epub 2012 May 9. PubMed 22575397 ↗
  • FDA Drug Safety Communication dated 26 July 2011 - accessed on 31 January 2019 at - http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm
  • Dewachter P, Mouton-Faivre C, Trechot P, Lleu JC, Mertes PM. Severe anaphylactic shock with methylene blue instillation. Anesth Analg. 2005 Jul;101(1):149-50, table of contents. doi: 10.1213/01.ANE.0000153497.60047.80. PubMed 15976222 ↗
  • Bezu C, Coutant C, Salengro A, Darai E, Rouzier R, Uzan S. Anaphylactic response to blue dye during sentinel lymph node biopsy. Surg Oncol. 2011 Mar;20(1):e55-9. doi: 10.1016/j.suronc.2010.10.002. Epub 2010 Nov 11. PubMed 21074413 ↗
  • Masannat YA, Hanby A, Horgan K, Hardie LJ. DNA damaging effects of the dyes used in sentinel node biopsy: possible implications for clinical practice. J Surg Res. 2009 Jun 15;154(2):234-8. doi: 10.1016/j.jss.2008.07.039. Epub 2008 Sep 4. PubMed 19181339 ↗
  • Wainwright M, Crossley KB. Methylene Blue--a therapeutic dye for all seasons? J Chemother. 2002 Oct;14(5):431-43. doi: 10.1179/joc.2002.14.5.431. PubMed 12462423 ↗
  • Silva ZS Jr, Bussadori SK, Fernandes KP, Huang YY, Hamblin MR. Animal models for photodynamic therapy (PDT). Biosci Rep. 2015 Sep 28;35(6):e00265. doi: 10.1042/BSR20150188. PubMed 26415497 ↗
  • Dai T, Tegos GP, Zhiyentayev T, Mylonakis E, Hamblin MR. Photodynamic therapy for methicillin-resistant Staphylococcus aureus infection in a mouse skin abrasion model. Lasers Surg Med. 2010 Jan;42(1):38-44. doi: 10.1002/lsm.20887. PubMed 20077489 ↗
  • Zolfaghari PS, Packer S, Singer M, Nair SP, Bennett J, Street C, Wilson M. In vivo killing of Staphylococcus aureus using a light-activated antimicrobial agent. BMC Microbiol. 2009 Feb 4;9:27. doi: 10.1186/1471-2180-9-27. PubMed 19193212 ↗
  • Fang CH, Fastenberg JH, Fried MP, Jerschow E, Akbar NA, Abuzeid WM. Antibiotic use patterns in endoscopic sinus surgery: a survey of the American Rhinologic Society membership. Int Forum Allergy Rhinol. 2018 Apr;8(4):522-529. doi: 10.1002/alr.22085. Epub 2018 Jan 15. PubMed 29334432 ↗
  • Shah SJ, Hawn VS, Zhu N, Fang CH, Gao Q, Akbar NA, Abuzeid WM. Postoperative Infection Rate and Associated Factors Following Endoscopic Sinus Surgery. Ann Otol Rhinol Laryngol. 2022 Jan;131(1):5-11. doi: 10.1177/00034894211007240. Epub 2021 Apr 9. PubMed 33834876 ↗
  • Virkkula P, Makitie AA, Vento SI. Surgical outcome and complications of nasal septal perforation repair with temporal fascia and periosteal grafts. Clin Med Insights Ear Nose Throat. 2015 Apr 29;8:7-11. doi: 10.4137/CMENT.S23230. eCollection 2015. PubMed 25987852 ↗
  • Dabrowska-Bien J, Skarzynski PH, Gwizdalska I, Lazecka K, Skarzynski H. Complications in septoplasty based on a large group of 5639 patients. Eur Arch Otorhinolaryngol. 2018 Jul;275(7):1789-1794. doi: 10.1007/s00405-018-4990-8. Epub 2018 May 16. PubMed 29770875 ↗
  • von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001 Jan 4;344(1):11-6. doi: 10.1056/NEJM200101043440102. PubMed 11136954 ↗
  • Kuehnert MJ, Kruszon-Moran D, Hill HA, McQuillan G, McAllister SK, Fosheim G, McDougal LK, Chaitram J, Jensen B, Fridkin SK, Killgore G, Tenover FC. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis. 2006 Jan 15;193(2):172-9. doi: 10.1086/499632. Epub 2005 Dec 15. PubMed 16362880 ↗
  • Khorvash F, Abdi F, Kashani HH, Naeini FF, Narimani T. Staphylococcus aureus in Acne Pathogenesis: A Case-Control Study. N Am J Med Sci. 2012 Nov;4(11):573-6. doi: 10.4103/1947-2714.103317. PubMed 23181229 ↗
  • Zanger P, Nurjadi D, Vath B, Kremsner PG. Persistent nasal carriage of Staphylococcus aureus is associated with deficient induction of human beta-defensin 3 after sterile wounding of healthy skin in vivo. Infect Immun. 2011 Jul;79(7):2658-62. doi: 10.1128/IAI.00101-11. Epub 2011 Apr 4. PubMed 21464083 ↗
  • Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005 Dec;5(12):751-62. doi: 10.1016/S1473-3099(05)70295-4. PubMed 16310147 ↗
  • National Healthcare Safety Network, Centers for Disease Control and Prevention. Surgical site infection (SSI) event. http://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf. Published January 2017.
  • Bachert C, Pawankar R, Zhang L, Bunnag C, Fokkens WJ, Hamilos DL, Jirapongsananuruk O, Kern R, Meltzer EO, Mullol J, Naclerio R, Pilan R, Rhee CS, Suzaki H, Voegels R, Blaiss M. ICON: chronic rhinosinusitis. World Allergy Organ J. 2014 Oct 27;7(1):25. doi: 10.1186/1939-4551-7-25. eCollection 2014. PubMed 25379119 ↗
  • Annys E, Jorissen M. Short term effects of antibiotics (Zinnat) after endoscopic sinus surgery. Acta Otorhinolaryngol Belg. 2000;54(1):23-8. PubMed 10719590 ↗
  • Fernandes SV. Postoperative care in functional endoscopic sinus surgery? Laryngoscope. 1999 Jun;109(6):945-8. doi: 10.1097/00005537-199906000-00020. PubMed 10369288 ↗
  • Jorissen M, Bachert C. Effect of corticosteroids on wound healing after endoscopic sinus surgery. Rhinology. 2009 Sep;47(3):280-6. doi: 10.4193/Rhin08.227. PubMed 19839251 ↗

Individual participant data

Plan to share: No — The trial will be conducted in accordance with the Data Protection Act 2018. The chief investigator will ensure that participant's anonymity is maintained throughout the study and following completion of the study. Pseudonymised data will be shared with the study Statistician who is an employee of the Trust and member of the study team. It will be extracted from REDCap and sent via encrypted email in a locked Excel document. After the analysis the data will be archived in Iron Mountain. No data will be shared outside of GSTT during the course of the study. Data will not be shared with the device manufacturer.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2024
First posted
Dec 13, 2024
StartActual
Jun 4, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06731881
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Jun 4, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jun 11, 2026

Study contacts

Claire Hopkins
Contact
Claire.Hopkins@gstt.nhs.uk
+442071887188 ext. 82215
Nora Haloob
Contact
Nora.Haloob@gstt.nhs.uk
+447737075302
Claire Hopkins
principal investigator · Guy's and St Thomas' NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion